Ruxolitinib alleviates DSS-induced acute ulcerative colitis by inhibiting STAT1 phosphorylation and reducing MDSC infiltration
Ruxolitinib effectively ameliorated DSS-induced acute colitis by reducing inflammation, modulating MDSC levels, and inhibiting STAT1 activation. These findings suggest that Ruxolitinib could be a promising therapeutic agent for UC, targeting both the immune response and the JAK/STAT1 signaling pathway.
Authors
- Vincent Kam Wai Wong (ORCID: https://orcid.org/0000-0002-2951-8108)
- Qinghua Yao (ORCID: https://orcid.org/0000-0002-0302-4433)
- Feng Xu (ORCID: https://orcid.org/0000-0002-1496-9141)
- Lu Xu (ORCID: https://orcid.org/0009-0007-6287-6832)
Institutions
- Macau University of Science and Technology (MO)
- Zhejiang Chinese Medical University (CN)
- University of Macau (MO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fphar.2025.1572534
- Citations
- 1
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Fundo para o Desenvolvimento das Ciências e da Tecnologia